Repare Therapeutics Stock Gross Profit

RPTX Stock

USD 3.32 0.17 5.40%

Repare Therapeutics fundamentals help investors to digest information that contributes to Repare Therapeutics' financial success or failures. It also enables traders to predict the movement of Repare Stock. The fundamental analysis module provides a way to measure Repare Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Repare Therapeutics stock.

	Last Reported	Projected for Next Year
Gross Profit	-80.1 M	-76.1 M
Gross Profit Margin	(1.57)	(1.64)

Gross Profit is likely to rise to about (76.1 M) in 2024. Gross Profit Margin is likely to drop to -1.64 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Repare Therapeutics Company Gross Profit Analysis

Repare Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Repare Therapeutics Gross Profit

15.11 M

Most of Repare Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repare Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Repare Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Repare Therapeutics is extremely important. It helps to project a fair market value of Repare Stock properly, considering its historical fundamentals such as Gross Profit. Since Repare Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Repare Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Repare Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Short Term Investments
Total Assets		0.98	0.95	-0.91	-0.82	0.47	0.61	0.86	0.49	0.98	1.0	0.96	0.99	0.96	0.9	0.65	0.83	0.6
Total Stockholder Equity	0.98		0.98	-0.88	-0.82	0.42	0.61	0.84	0.31	1.0	0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Net Tangible Assets	0.95	0.98		-0.83	-0.86	0.47	0.67	0.87	0.26	0.98	0.95	0.99	0.94	0.99	0.94	0.6	0.89	0.64
Net Debt	-0.91	-0.88	-0.83		0.56	-0.6	-0.37	-0.62	-0.51	-0.88	-0.91	-0.81	-0.94	-0.81	-0.7	-0.34	-0.57	-0.22
Retained Earnings	-0.82	-0.82	-0.86	0.56		-0.45	-0.89	-0.99	-0.27	-0.82	-0.81	-0.9	-0.78	-0.9	-0.87	-0.64	-0.96	-0.77
Accounts Payable	0.47	0.42	0.47	-0.6	-0.45		0.58	0.44	0.39	0.42	0.46	0.44	0.52	0.44	0.44	-0.29	0.31	-0.14
Net Receivables	0.61	0.61	0.67	-0.37	-0.89	0.58		0.82	0.16	0.61	0.61	0.69	0.6	0.69	0.76	0.33	0.75	0.59
Capital Surpluse	0.86	0.84	0.87	-0.62	-0.99	0.44	0.82		0.34	0.84	0.85	0.91	0.82	0.91	0.85	0.68	0.96	0.75
Total Liab	0.49	0.31	0.26	-0.51	-0.27	0.39	0.16	0.34		0.31	0.49	0.31	0.5	0.31	0.36	0.31	0.24	0.2
Net Invested Capital	0.98	1.0	0.98	-0.88	-0.82	0.42	0.61	0.84	0.31		0.98	0.98	0.97	0.98	0.9	0.63	0.84	0.61
Total Current Assets	1.0	0.98	0.95	-0.91	-0.81	0.46	0.61	0.85	0.49	0.98		0.96	0.99	0.96	0.9	0.65	0.83	0.61
Capital Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96		0.94	1.0	0.94	0.66	0.93	0.69
Net Working Capital	0.99	0.97	0.94	-0.94	-0.78	0.52	0.6	0.82	0.5	0.97	0.99	0.94		0.94	0.88	0.57	0.78	0.53
Common Stock	0.96	0.98	0.99	-0.81	-0.9	0.44	0.69	0.91	0.31	0.98	0.96	1.0	0.94		0.94	0.66	0.93	0.69
Property Plant Equipment	0.9	0.9	0.94	-0.7	-0.87	0.44	0.76	0.85	0.36	0.9	0.9	0.94	0.88	0.94		0.64	0.89	0.76
Current Deferred Revenue	0.65	0.63	0.6	-0.34	-0.64	-0.29	0.33	0.68	0.31	0.63	0.65	0.66	0.57	0.66	0.64		0.74	0.91
Short Term Debt	0.83	0.84	0.89	-0.57	-0.96	0.31	0.75	0.96	0.24	0.84	0.83	0.93	0.78	0.93	0.89	0.74		0.83
Short Term Investments	0.6	0.61	0.64	-0.22	-0.77	-0.14	0.59	0.75	0.2	0.61	0.61	0.69	0.53	0.69	0.76	0.91	0.83

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Repare Therapeutics

Gross Profit Over Time

According to the company disclosure, Repare Therapeutics reported 15.11 M of gross profit. This is 99.33% lower than that of the Biotechnology sector and 98.41% lower than that of the Health Care industry. The gross profit for all United States stocks is 99.94% higher than that of the company.

Repare Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Repare Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Repare Therapeutics could also be used in its relative valuation, which is a method of valuing Repare Therapeutics by comparing valuation metrics of similar companies.

Repare Therapeutics is currently under evaluation in gross profit category among its peers.

Repare Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repare Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repare Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Repare Fundamentals

	Return On Equity	-0.41
	Return On Asset	-0.23
	Profit Margin	(1.26) %
	Operating Margin	(1.39) %
	Current Valuation	(42.96 M)
	Shares Outstanding	42.51 M
	Shares Owned By Insiders	0.95 %
	Shares Owned By Institutions	83.62 %
	Number Of Shares Shorted	749.74 K
	Price To Book	0.77 X
	Price To Sales	2.01 X
	Revenue	51.13 M
	Gross Profit	15.11 M
	EBITDA	(114.27 M)
	Net Income	(93.8 M)
	Cash And Equivalents	282.09 M
	Cash Per Share	6.73 X
	Total Debt	3.41 M
	Debt To Equity	0.03 %
	Current Ratio	7.35 X
	Book Value Per Share	4.12 X
	Cash Flow From Operations	(127.16 M)
	Short Ratio	7.12 X
	Earnings Per Share	(1.99) X
	Target Price	12.5
	Number Of Employees	179
	Beta	0.71
	Market Capitalization	133.91 M
	Total Asset	253.9 M
	Retained Earnings	(333.11 M)
	Working Capital	204.61 M
	Net Asset	253.9 M

About Repare Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Repare Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repare Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repare Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC